RxDoctor Payments Data

Elizabeth Anderson

Psychiatric/Mental Health · Clarksville, TNNPI 1851777015

Payments from drug & device makers

$6,339in general payments, 2019–2025

Across 335 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$859
  • Neurocrine Biosciences, Inc.$818
  • AbbVie$731
  • Otsuka America Pharmaceutical, Inc.$512
  • E.r. Squibb & Sons, L.L.C.$484
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$6,04895%
  • Education$2915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,339 in reported general payments places this provider in the 90th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$6,151
Medicare patients
19
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$111,023
AristadaAripiprazole Lauroxil23$68,932
VraylarCariprazine Hcl46$66,792
LatudaLurasidone Hcl13$19,067
Oxcarbazepine49$2,213
Lurasidone Hcl35$1,839
Buspirone Hcl103$1,542
Aripiprazole43$1,535
Sertraline Hcl92$1,192
Mirtazapine71$1,171
Haloperidol Decanoate26$1,041
Vilazodone Hcl13$1,027
Divalproex Sodium ErDivalproex Sodium22$788
Hydroxyzine Hcl57$644
Prazosin Hcl56$596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$818$111,02313 claims
Alkermes, Inc.Aristada$1,147$68,93223 claims
AbbVieVraylar$731$66,79246 claims
Sunovion Pharmaceuticals Inc.Latuda$13$19,06713 claims
Teva Pharmaceuticals USA, Inc.Loxapine$859$52416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Clarksville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →